Novel 5‐Aminosalicylic Acid Formulations in Ulcerative Colitis:Old Dog, New Tricks

Gastroenterology Nursing

Volumn 31, Issue 4, 2008, Pages 286-292

  Wilson, Joanne ^a  

^a Rocky Mountain Clinical Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE;

DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; MONITORING; NURSE ATTITUDE; NURSE PATIENT RELATIONSHIP; NURSING; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT EDUCATION; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; STATISTICS; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MONITORING, PHYSIOLOGIC; NURSE'S ROLE; NURSE-PATIENT RELATIONS; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 56049101168     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/01.SGA.0000334035.94370.f6     Document Type: Article

References (45)

1. Asacol prescribing information. (2007).
2. Bresci, G., Parisi, G., Bertoni, M., & Capria, A. (2002). Long-term maintenance treatment in ulcerative colitis: A 10-year follow-up. Digestive & Liver Disease, 34(6), 419-423.
3. Brunner, M., Greinwald, R., Kletter, K., Kvaternik, H., Corrado, M., Eichler, H., et al. (2003). Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Alimentary Pharmacology & Therapeutics, 17(9), 1163-1169.
4. Carter, M. J., Lobo, A. J., & Travis, S. P. (2004). Guidelines for the management of inflammatory bowel disease in adults. Gut, 53(Suppl. V), v1-v16
5. Casellas, F., Arenas, J. I., Baudet, J. S., Fabregas, S., Garcia, N., Gelabert, J., et al. (2005). Impairment of health-related quality of life in patients with inflammatory bowel disease: A Spanish multicenter study. Inflammatory Bowel Disease, 11(5), 488-496.
6. Casellas, F., Lopez-Vivancos, J., Badia, X., Vilaseca, J., & Malagelada, J. R. (2001). Influence of inflammatory bowel disease on different dimensions of quality of life. European Journal of Gastroenterology & Hepatology, 13(5), 567-572.
7. Cohen, R. D., Woseth, D. M., Thisted, R. A., & Hanauer, S. B. (2000). A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. American Journal of Gastroenterology, 95, 1263-1276.
8. d'Albasio, G., Pacini, F., Camarri, E., Messori, A., Trallori, G., Bonanomi, A. G., et al. (1997). Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. American Journal of Gastroenterology, 92(7), 1143-1147.
9. De Vos, M., Verdievel, H., Schoonjans, R., Praet, M., Bogaert, M., & Barbier, F. (1992). Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut, 33(10), 1338-1342.
10. Dignass, A., Stijnen, T., Mross, M. R., Vermeire, S., Veerman, H., & Bhatt, A. (2007). Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: Demographic and baseline rata of a 12 month single blind randomised controlled trial. Gastroenterology, 132, A-502 (Abstract T1265).
11. Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001). The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut, 48(4), 526-535.
12. Farup, P., Hinterleitner, T., Lukas, M., Hebuterne, X., Rachmilewitz, D., Campieri, M., et al. (2001). Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Disease, 7(3), 237-242.
13. Frieri, G., Giacomelli, R., Pimpo, M., Palumbo, G., Passacantando, A., Pantaleoni, G., et al. (2000). Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut, 47(3), 410-414.
14. Frieri, G., Pimpo, M. T., Palumbo, G. C., Onori, L., Viscido, A., Latella, G., et al. (1999). Rectal and colonic mesalazine concentration in ulcerative colitis: Oral vs. oral plus topical treatment. Alimentary Pharmacology & Therapeutics, 13(11), 1413-1417.
15. Ghosh, S., Shand, A., & Ferguson, A. (2000). Ulcerative colitis. British Medical Journal, 320(7242), 1119-1123.
16. Gionchetti, P., Ardizzone, S., Benvenuti, M. E., Bianchi Porro, G., Biasco, G., Cesari, P., et al. (1999). A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: A randomized controlled multicentre trial. Alimentary Pharmacology & Therapeutics, 13(3), 381-388.
17. Han, S. W., McColl, E., Barton, J. R., James, P., Steen, I. N., & Welfare, M. R. (2005). Predictors of quality of life in ulcerative colitis: The importance of symptoms and illness representations. Inflammatory Bowel Disease, 11(1), 24-34.
18. Hanauer, S., Sandborn, W., Kornbluth, A., Hardi, R., Regalli, G., & Yeh, C. (2005). Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) versus 2.4 g/day (400 mg tablet) for treatment of moderately active ulcerative colitis: combined analysis of two randomised, double-blind, controlled trials. Gastroenterology, 128(4) (Suppl. 2), A-74-75 (Abstract 492).
19. Hanauer, S., Sandborn, W., Kornbluth, A., Katz, S., Safdi, M., Woogen, S., et al. (2005). Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial. American Journal of Gastroenterology, 100, 2478-2485.
20. Hanauer, S. B., Sandborn, W. J., Dallaire, C., Archambault, A., Yacyshyn, B., Yeh, C., et al. (2007). Efficacy and safety of Asacol 4.8 g/day (800 mg tablets) compared to Asacol 2.4 g/day (400 mg tablets) in the treatment of mild to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology, 21(12), 827-834.
21. Kamm, M. A., Colombel, J. F., Kornbluth, A., Diebold, R., Barrett, K., Karlstadt, R. G., et al. (2007). A randomized comparison of once-versus twice-daily MMX mesalamine for the maintenance of remission in mild-to-moderate ulceratice colitis. Gastroenterology, 132, A-510 (Abstract T1296).
22. Kamm, M. A., Sandborn, W. J., Gassull, M., Schreiber, S., Jackowski, L., Butler, T., et al. (2007). Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology, 132(1), 66-75.
23. Kane, S., Huo, D., Aikens, J., & Hanauer, S. (2003). Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine, 114, 39-43.
24. Kane, S., Huo, D., & Magnanti, K. (2003). A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology & Hepatology, 1(3), 170-173.
25. Kane, S. V., Cohen, R. D., Aikens, J. E., & Hanauer, S. B. (2001). Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology, 96(10), 2929-2933.
26. Kornbluth, A., & Sachar, D. B. (2004). Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology, 99(7), 1371-1385.
27. Kruis, W., Gorelov, W., Kludelis, G., Raez, I., Pokrotnieks, J., Horynski, M., et al. (2007). Once daily dosing of 3g mesalamine (Salofalk® granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterology, 132, Abstract 898.
28. Lichtenstein, G. R., Kamm, M. A., Boddu, P., Gubergrits, N., Lyne, A., Butler, T., et al. (2007). Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology & Hepatology, 5, 95-102.
29. Lichtenstein, G. R., Kamm, M. A., Sandborn, W. J., Lyne, A., Butler, T., & Joseph, R. E. (2008). MMX mesalamine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in patient sub-populations. Alimentary Pharmacology & Therapeutics, 27(11), 1094-1102.
30. Lim, W. C., & Hanauer, S. B. (2004). Controversies with aminosalicylates in inflammatory bowel disease. Review of Gastroenterology Disorders, 4(3), 104-117.
31. Loftus, E. V. (2006). A practical perspective on ulcerative colitis: Patients' needs from aminosalicylate therapies. Inflammatory Bowel Disease, 12(12), 1107-1113.
32. Meucci, G., Fasoli, R., Saibeni, S., Valpiani, D., Gullotta, R., Colombo, E., et al. (2006). Prognostic significance of endoscopy remission in patients with active ulcerative colitis treated with oral and topical mesalazine: Preliminary results of a prospective, multicenter study. Gastroenterology, 130, A-197(Abstract S1302).
33. National Digestive Diseases Information Clearinghouse. (2006). Ulcerative colitis.
34. Pentasa prescribing information. (2007).
35. Prantera, C., Viscido, A., Biancone, L., Francavilla, A., Giglio, L., & Campieri, M. (2005). A new oral delivery system for 5-ASA: Preliminary clinical findings for MMx. Inflammatory Bowel Disease, 11(5), 421-427.
36. Raedler A., Behrens, C., & Bias, P. (2004). Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis—results from a randomized-controlled trial. Alimentary Pharmacology & Therapeutics, 20(11/12), 1353-1363.
37. Sandborn, W. J., Kamm, M. A., Lichtenstein, G. R., Lyne, A., Butler, T., & Joseph, R. E. (2007). Multi Matrix System (MMX®) mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Alimentary Pharmacology & Therapeutics, 26(2), 205-215.
38. Schmidt, C., & Stallmach, A. (2005). Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterologica Dietologica, 51(2), 127-145.
39. Shale, M. J., & Riley S. A. (2003). Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 18(2), 191-198.
40. Tenjarla, S., Romasanta, V., Zeijdner, E., Villa, R., & Moro, L. (2007). Release of 5-aminosalicylate from the MMX™ mesalamine tablet during transit through a simulated gastrointestinal tract system. Advances in Therapy, 24(4), 826-840.
41. Turnbough, L., & Wilson, L. (2007). “Take your medicine”: Nonadherence issues in patients with ulcerative colitis. Gastroenterology Nursing, 30(3), 212-217.
42. van Staa, T. P., Card, T., Logan, R. F., & Leufkens, H. G. (2005). 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: A large epidemiological study. Gut, 54(11), 1573-1578.
43. Velayos, F. S., Loftus, E. V., Jess, T., Harmsen, W. S., Bida, J., Zinsmeister, A. R., et al. (2006). Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology, 130(7), 1941-1949.
44. Velayos, F. S., Terdiman, J. P., & Walsh, J. M. (2005). Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and metaanalysis of observational studies. American Journal of Gastroenterology, 100(6), 1345-1353.
45. Wilding, I., Behrens, C., Tardif, S., Wray, H., Bias, P., & Albrecht, W. (2003). Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Alimentary Pharmacology & Therapeutics, 17(9), 1153-1162.